When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations
Medi-Cal dropping coverage Perhaps the most significant change for low-income populations was Medi-Cal, California Medicaid program, dropping GLP-1 weight loss coverage effective January 1, 2026
For us, it was very important to share and make sure that we have the right standards in place. Purification and Analytics Villain said the primary bottleneck has shifted over time
PlexusDx partners exclusively with licensed 503A facilitiesnever 503B manufacturersensuring pharmaceutical-grade quality at a fraction of brand-name costs
Special populations and considerations People with type 2 diabetes Discontinuing GLP-1 medications when you have type 2 diabetes requires additional monitoring
Secondly, we examined the BT of E